Management of refractory rheumatoid arthritis

被引：0

作者：

van de Putte, LBA ^{[1
]}

Kroot, EJA ^{[1
]}

van Riel, PLCM ^{[1
]}

机构：

[1] Univ Nijmegen Hosp, Dept Rheumatol, NL-6500 HB Nijmegen, Netherlands

来源：

RHEUMATOLOGY | 1999年 / 38卷

关键词：

rheumatoid arthritis; treatment; refractory; DMARDs; corticosteroids; tumour necrosis factor alpha; methotrexate;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Based on the results of a MEDLINE search (1992-1997), the term 'refractory rheumatoid arthritis' (refractory RA) is ill-defined, in terms of both patient characterization and description of previous treatments. Current strategies of management of refractory RA include increasing disease-modifying anti-rheumatic drug dosage above standard dosage regimens, using combination therapy, and adding or increasing the dosage of corticosteroids. Options for further strategies include target-oriented biological agents (e.g. anti-tumour necrosis factor), gene therapy, stem-cell treatment and oral tolerance induction.

引用

页码：32 / 34

页数：3

共 22 条

[1]

AHERN M, 1997, THERAPY SYSTEMIC RHE, P183

[2] Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee [J].

Bakker, AC ;

Joosten, LAB ;

Arntz, OJ ;

Helsen, MMA ;

Bendele, AM ;

vandeLoo, FAJ ;

vandenBerg, WB .

ARTHRITIS AND RHEUMATISM, 1997, 40 (05) :893-900

[3] Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [J].

Boers, M ;

Verhoeven, AC ;

Markusse, HM ;

vandeLaar, MAFJ ;

Westhovens, R ;

vanDenderen, JC ;

vanZeben, D ;

Dijkmans, BAC ;

Peeters, AJ ;

Jacobs, P ;

vandenBrink, HR ;

Schouten, HJA ;

vanderHeijde, DMFM ;

Boonen, A ;

vanderLinden, S .

LANCET, 1997, 350 (9074) :309-318

[4] RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS [J].

ELLIOTT, MJ ;

MAINI, RN ;

FELDMANN, M ;

KALDEN, JR ;

ANTONI, C ;

SMOLEN, JS ;

LEEB, B ;

BREEDVELD, FC ;

MACFARLANE, JD ;

BIJL, H ;

WOODY, JN .

LANCET, 1994, 344 (8930) :1105-1110

[5] THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY CORE SET OF DISEASE-ACTIVITY MEASURES FOR RHEUMATOID-ARTHRITIS CLINICAL-TRIALS [J].

FELSON, DT ;

ANDERSON, JJ ;

BOERS, M ;

BOMBARDIER, C ;

CHERNOFF, M ;

FRIED, B ;

FURST, D ;

GOLDSMITH, C ;

KIESZAK, S ;

LIGHTFOOT, R ;

PAULUS, H ;

TUGWELL, P ;

WEINBLATT, M ;

WIDMARK, R ;

WILLIAMS, HJ ;

WOLFE, F .

ARTHRITIS AND RHEUMATISM, 1993, 36 (06) :729-740

[6] USE OF SHORT-TERM EFFICACY TOXICITY TRADEOFFS TO SELECT 2ND-LINE DRUGS IN RHEUMATOID-ARTHRITIS - A METAANALYSIS OF PUBLISHED CLINICAL-TRIALS [J].

FELSON, DT ;

ANDERSON, JJ ;

MEENAN, RF .

ARTHRITIS AND RHEUMATISM, 1992, 35 (10) :1117-1125

[7]

Haagsma CJ, 1997, BRIT J RHEUMATOL, V36, P1082

[8] Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [J].

Moreland, LW ;

Baumgartner, SW ;

Schiff, MH ;

Tindall, EA ;

Fleischmann, RM ;

Weaver, AL ;

Ettlinger, RE ;

Cohen, S ;

Koopman, WJ ;

Mohler, K ;

Widmer, MB ;

Blosch, CM .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :141-147

[9]

ODell J, 1996, ARTHRITIS RHEUM, V39, pR12

[10]

PINCUS T, 1992, J RHEUMATOL, V19, P1051

← 1 2 3 →